Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 5891

MacroGenics stops work on a bispecific; Third Arc Bio makes a deal with Adagene

$
0
0
Plus, news about Modulight Biotherapeutics, T-Therapeutics and EnGene: 🛑 MacroGenics cans PD-1xCTLA-4 bispecific in prostate cancer: The company said it would stop development of lorigerlimab in prostate ...

Viewing all articles
Browse latest Browse all 5891

Trending Articles